{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:29:04Z","timestamp":1790314144029,"version":"4.1.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>More than 80% of patients with advanced-stage Hodgkin lymphoma are now cured with contemporary treatment approaches. The ongoing challenge is how to further improve outcomes by identifying both high-risk patients who may benefit from more intensive frontline therapy to reduce the risk of relapse as well as lower-risk patients who may do just as well with less intensive therapy. Numerous trials have used an interim positron emission tomography (PET) response-adapted approach to evaluate early escalation or deescalation of therapy for patients with a positive or negative interim PET scan, respectively. Recent trials have incorporated novel agents, including brentuximab vedotin (BV) and the immune checkpoint inhibitors, in the frontline setting. Based on results of the ECHELON-1 trial, the Food and Drug Administration approved BV in combination with adriamycin, vinblastine, and dacarbazine chemotherapy for stage III to IV Hodgkin lymphoma. Improved methods to assess higher risk at diagnosis using quantitative PET metrics, such as metabolic tumor volume and total lesion glycolysis, and incorporation of emerging biomarkers may further refine patient selection for more intensive upfront therapy. The ultimate goal is to achieve the highest level of efficacy for an individual patient while minimizing the short- and long-term toxicities.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.200","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:59Z","timestamp":1555452839000},"page":"200-206","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Risk-adapted therapy for advanced-stage Hodgkin lymphoma"],"prefix":"10.1182","volume":"2018","author":[{"given":"Michael A.","family":"Spinner","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111521525882600_B1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.6004\/jnccn.2018.0013","article-title":"NCCN guidelines insights: Hodgkin lymphoma, version 1.2018","volume":"16","author":"Hoppe","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2019111521525882600_B2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111521525882600_B3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111521525882600_B4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cncr.30979","article-title":"Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: an adult intergroup (E2496) and Children\u2019s Oncology Group (COG AHOD0031) comparative analysis","volume":"124","author":"Henderson","year":"2018","journal-title":"Cancer"},{"issue":"9828","key":"2019111521525882600_B5","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"2019111521525882600_B6","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/HS9.0000000000000005","article-title":"Reduced-intensity chemotherapy in patients with advanced-stage Hodgkin lymphoma: updated results of the open-label, international, randomised phase 3 HD15 trial by the German Hodgkin Study Group","volume":"1","author":"Engert","year":"2017","journal-title":"HemaSphere"},{"issue":"3","key":"2019111521525882600_B7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111521525882600_B8","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","article-title":"ABVD (8 cycles) versus BEACOPP (4 escalated cycles \u2265 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial","volume":"25","author":"Mounier","year":"2014","journal-title":"Ann Oncol"},{"issue":"11","key":"2019111521525882600_B9","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","article-title":"Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: a study by fondazione Italiana Linfomi","volume":"34","author":"Merli","year":"2016","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111521525882600_B10","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score \u2265 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup Trial","volume":"34","author":"Carde","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111521525882600_B11","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.2012.47.9774","article-title":"Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the German Hodgkin Study Group","volume":"31","author":"Wongso","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111521525882600_B12","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2010-05-285379","article-title":"BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children\u2019s Oncology Group","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111521525882600_B13","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111521525882600_B14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111521525882600_B15","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2967\/jnumed.109.073197","article-title":"18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma","volume":"51","author":"Cerci","year":"2010","journal-title":"J Nucl Med"},{"issue":"24","key":"2019111521525882600_B16","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111521525882600_B17","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"issue":"8","key":"2019111521525882600_B18","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on Interim-PET-Scan in Lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111521525882600_B19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"2019111521525882600_B20","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood.V130.Suppl_1.651.651","article-title":"Nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from the phase 2 Checkmate 205 Study","volume":"130","author":"Ramchandren","year":"2017","journal-title":"Blood"},{"issue":"17","key":"2019111521525882600_B21","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"key":"2019111521525882600_B22","first-page":"T003","article-title":"Long-term follow-up of SWOG S0816: response-adapted therapy of advanced stage Hodgkin lymphoma using early interim FDG-PET imaging","volume":"101","author":"Friedberg","year":"2016","journal-title":"Haematologica"},{"issue":"25","key":"2019111521525882600_B23","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111521525882600_B24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two abvd cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10114","key":"2019111521525882600_B25","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"2019111521525882600_B26","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: final results of the phase II part of the HD0801 study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111521525882600_B27","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bjh.14734","article-title":"Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET\/CT is beneficial: a prospective multicentre trial of 355 patients","volume":"178","author":"Dann","year":"2017","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111521525882600_B28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.V126.23.577.577","article-title":"Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: interim analysis of the AHL2011 Lysa Study","volume":"126","author":"Casasnovas","year":"2015","journal-title":"Blood"},{"issue":"18","key":"2019111521525882600_B29","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111521525882600_B30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111521525882600_B31","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"2019111521525882600_B32","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"2019111521525882600_B33","first-page":"S112","article-title":"Brentuximab vedotin plus chemotherapy in high risk advanced-staged classical Hodgkin lymphoma (CHL) patients: results of pre-specified sub-group analyses from the ECHELON-1 study","volume":"2018","author":"Hutchings","year":"2018","journal-title":"Haematologica"},{"key":"2019111521525882600_B34","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1200\/JCO.2018.36.15_suppl.7539","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): impact of cycle 2 PET result on modified progression-free survival (mPFS)","volume":"36","author":"Chen","year":"2018","journal-title":"J Clin Oncol"},{"key":"2019111521525882600_B35","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.1200\/JCO.2018.36.15_suppl.7541","article-title":"Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results","volume":"36","author":"Ramchandren","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111521525882600_B36","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","article-title":"Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin\u2019s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group","volume":"18","author":"Eichenauer","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"2019111521525882600_B37","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","article-title":"Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma","volume":"41","author":"Kanoun","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2019111521525882600_B38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2017-04-773838","article-title":"Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation","volume":"131","author":"Akhtari","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2019111521525882600_B39","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2019111521525882600_B40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hon.2437_18","article-title":"Can baseline PET-CT features predict outcomes in advanced Hodgkin lymphoma? A prospective evaluation of UK patients in the RATHL trial (CRUK\/07\/033)","volume":"35","author":"Pike","year":"2017","journal-title":"Hematol Oncol"},{"issue":"10","key":"2019111521525882600_B41","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1016\/S2352-3026(16)30108-9","article-title":"The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin\u2019s lymphoma: a retrospective, European, multicentre cohort study","volume":"3","author":"Agostinelli","year":"2016","journal-title":"Lancet Haematol"},{"issue":"22","key":"2019111521525882600_B42","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2019111521525882600_B43","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"key":"2019111521525882600_B44","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V130.Suppl_1.733.733","article-title":"Sequential brentuximab vedotin (Bv) before and after adriamycin, vinblastine, and dacarbazine (Bv-AVD) for older patients with untreated classical hodgkin lymphoma (cHL): final results from a multicenter phase II study","volume":"130","author":"Evens","year":"2017","journal-title":"Blood"},{"issue":"15","key":"2019111521525882600_B45","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2017-09-772640","article-title":"Optimizing therapy in advanced-stage Hodgkin lymphoma","volume":"131","author":"Lim","year":"2018","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/200\/1252136\/hem01827.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/200\/1252136\/hem01827.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T03:14:16Z","timestamp":1663298056000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/200\/277570\/Riskadapted-therapy-for-advancedstage-Hodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.200","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}